Cargando…
NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
We compared minimal/measurable residual disease (MRD) levels evaluated by routinely used real-time quantitative polymerase chain reaction (qPCR) patient-specific assays and by next-generation sequencing (NGS) approach in 780 immunoglobulin (IG) and T-cell receptor (TR) markers in 432 children with B...
Autores principales: | Svaton, Michael, Skotnicova, Aneta, Reznickova, Leona, Rennerova, Andrea, Valova, Tatana, Kotrova, Michaela, van der Velden, Vincent H. J., Brüggemann, Monika, Darzentas, Nikos, Langerak, Anton W., Zuna, Jan, Stary, Jan, Trka, Jan, Fronkova, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651772/ https://www.ncbi.nlm.nih.gov/pubmed/36240445 http://dx.doi.org/10.1182/blood.2022017003 |
Ejemplares similares
-
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022) -
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
por: Ferrero, Simone, et al.
Publicado: (2022) -
Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study
por: van der Velden, Vincent H. J., et al.
Publicado: (2021) -
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
por: Brüggemann, Monika, et al.
Publicado: (2019) -
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
por: Loke, Justin, et al.
Publicado: (2023)